Skip to content

Free cash flow at other companies

ALN
Alnylam PharmaceuticalsALNY
$48.67M+138%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$109.4M-102%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$130.75M-22.2%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.32M+9.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%

Valuation

See full
Market cap$2.13B+106%
Enterprise value$2.08B+100%
P/S32.2×+9.5×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Calculated from Intellia Therapeutics’s reported figures.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's free cash flow?
Intellia Therapeutics (NTLA) reported free cash flow of -$117.43M in Q1 2026.
How has Intellia Therapeutics's free cash flow changed year-over-year?
Intellia Therapeutics's free cash flow increased by 21.5% year-over-year, from -$149.67M to -$117.43M.
What is the long-term trend for Intellia Therapeutics's free cash flow?
Over 4 years (2021 to 2025), Intellia Therapeutics's free cash flow has grown at a 13.6% compound annual growth rate (CAGR), from -$237.79M to -$395.87M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.